Halozyme Therapeutics Inc (NAS:HALO)
$ 45.44 0.47 (1.05%) Market Cap: 5.78 Bil Enterprise Value: 6.76 Bil PE Ratio: 18.78 PB Ratio: 32.46 GF Score: 87/100

Halozyme Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 04:30PM GMT
Release Date Price: $20.13 (-0.49%)
Jessica Macomber Fye
JP Morgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. My name is Jess Fye. I'm one of the biotech analysts at JPMorgan, and we're continuing the 2020 health care conference today with Halozyme.

We're going to host a Q&A session with the management team right after this presentation. It's just down the hall in the Yorkshire Room. So come to that if you want to hear more. But for the presentation, I'm going to turn it over to the company's CEO, Helen Torley.

Helen I. Torley
Halozyme Therapeutics, Inc. - President, CEO & Director

Thank you, Jess, and thank you, everybody, for joining us today. In November 2019, after the negative data on PEGPH20, we rapidly transitioned Halozyme to become an ENHANZE-only company, focusing on our ENHANZE business. We rapidly restructured the company, reducing our expense base. And I'm very pleased to announce that 2020 will be our first year of sustainable profitability, with a projection of earnings per share of $0.60 to $0.75 in 2020. And this is just the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot